Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborators:

Walter Reed Army Institute of Research (WRAIR)

Royal Thai Ministry of Public Health

Mahidol University

Armed Forces Research Institute of Medical Sciences, Thailand

Sanofi Pasteur, a Sanofi Company

Global Solutions for Infectious Diseases

Information provided by (Responsible Party):

U.S. Army Medical Research and Materiel Command

ClinicalTrials.gov Identifier:

NCT00337181

First received: June 14, 2006

Last updated: December 30, 2015

Last verified: December 2015

History of Changes

Purpose

This protocol will study the clinical course of HIV-infection among volunteers who have received either a placebo injection or the experimental vaccine combination of ALVAC-HIV and AIDSVAX B/E prior to HIV-1 infection. The study will assess whether those who received the experimental vaccine combination have a slower progression of HIV disease compared to those who received the placebo injection.

Condition
HIV-1


Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E.

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by U.S. Army Medical Research and Materiel Command:


Estimated Enrollment:	130
Study Start Date:	May 2006
Estimated Study Completion Date:	June 2017
Primary Completion Date:	December 2006 (Final data collection date for primary outcome measure)

Detailed Description:

Prospective cohort study of the clinical course of HIV-1 infection occurring after candidate HIV-1 vaccination (breakthrough infection) with ALVAC-HIV (vcP1521) and AIDSVAX B/E. This study will enroll volunteers who become HIV-infected during the course of follow up in a phase III preventive HIV vaccine trial conducted in Rayong and Chon Buri, Thailand. Volunteers will be enrolled in this protocol to provide additional long-term follow up to establish whether differences in viral load after infection (comparing vaccine to placebo) are associated with altered disease outcomes, as well as provide more detailed immunologic and virologic assessment of these volunteers.

Eligibility


Ages Eligible for Study:	18 Years to 31 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

All individuals who become HIV-infected after receiving experimental vaccine or placebo in the RV144 clinical tria if they received at least injection.
The volunteer must give written, informed consent.

Exclusion Criteria:

Persons who have a medical or psychiatric disorder, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
Persons who become HIV-infected after the completion of the RV144 protocol.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00337181

Locations


Thailand
Chon Buri Regional Hospital
Muang District, Chon Buri Province, Thailand, 20000

Sponsors and Collaborators

U.S. Army Medical Research and Materiel Command

Walter Reed Army Institute of Research (WRAIR)

Royal Thai Ministry of Public Health

Mahidol University

Armed Forces Research Institute of Medical Sciences, Thailand

Sanofi Pasteur, a Sanofi Company

Global Solutions for Infectious Diseases

Investigators


Principal Investigator:	Supachai Rerks-Ngarm, MD	Ministry of Health, Thailand

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, de Souza MS, Andrews C, Francis D, Adams E, Flores J, Gurunathan S, Tartaglia J, O'Connell RJ, Eamsila C, Nitayaphan S, Ngauy V, Thongcharoen P, Kunasol P, Michael NL, Robb ML, Gilbert PB, Kim JH. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis. 2013 Apr 15;207(8):1195-205. doi: 10.1093/infdis/jis478. Epub 2012 Jul 26.


Responsible Party:	U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov Identifier:	NCT00337181 History of Changes
Other Study ID Numbers:	A-11048 RV152 CBER BB IND-8795
Study First Received:	June 14, 2006
Last Updated:	December 30, 2015
Health Authority:	United States: Office of the Surgeon General United States: US Medical Materiel Agency United States: Federal Government

Keywords provided by U.S. Army Medical Research and Materiel Command:


HIV-1 Natural History HIV vaccine Thailand

Additional relevant MeSH terms:


Vaccines Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 23, 2016

To Top